| • eGenesis, a biotechnology company focused on utilizing genome editing technology in medical procedures, raised a $38 million in Series A funding. Biomatics Capital and ARCH Venture Partners led the round, with participation from Khosla Ventures, Alta Partners, Alexandria Venture Investments, Heritage Provider Network, Berggruen Holdings North America, Uprising, and Fan Ventures.
• Peloton Therapeutics, a Dallas drug discovery and development company, raised $22.2 million in additional Series D funding, closing the round at $74.6 million.
• 908 Devices, a Boston developer of analytical devices for chemical and biomolecule analysis, raised $20 million in funding. Investors include Tao Capital Partners, Cormorant Asset Management, Saudi Aramco Energy Ventures, ARCH Venture Partners, Razor’s Edge Ventures, Schlumberger, and Casdin Capital.
• NeuraLace, a San Diego, Calif. developer of non-opioid pain reduction treatment, raised $2 million in funding from FusionX Ventures. |
